Sign In
Buy ARVN
$7.70
-0.300 (-3.75%)
At Close: Jun 03, 2026
Arvinas to Present at the UBS Global Healthcare Virtual Conference
04:30pm, Thursday, 20'th May 2021
NEW HAVEN, Conn., May 20, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today annou
Arvinas Among Top Shorts Today As Dow, S&P 500, And Nasdaq Climb For Another Consecutive Day
11:09am, Friday, 14'th May 2021
The Dow Jones climbed 220 points, the S&P 500 gained 0.8%, and the Nasdaq recovered another 1%. If you're looking for a way to play this market, the deep learning algorithms at Q.ai have crunched the
Arvinas Signs Lease for New Space Within Downtown Crossing Development in New Haven
02:52pm, Tuesday, 04'th May 2021
– Company to lease approximately 160,000-square-feet to allow continued growth and expansion of operations – – Company to lease approximately 160,000-square-feet to allow continued growth and ex
Arvinas, Inc. (ARVN) Reports Q1 Loss, Tops Revenue Estimates
09:47am, Tuesday, 04'th May 2021
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -7.69% and 41.37%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Top Stocks To Short Today As Jobless Claims And Retail Sales Crush Estimates
11:24am, Thursday, 15'th Apr 2021
The Dow Jones rose over 200 points, the S&P 500 gained 0.7%, and the Nasdaq advanced 1% with excitement over lower-than-expected jobless claims and higher-than-expected retail sales. Make the most of
Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021
04:30pm, Monday, 05'th Apr 2021
NEW HAVEN, Conn., April 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann
Arvinas to Participate in Upcoming Virtual Investor Conferences
04:30pm, Wednesday, 10'th Mar 2021
NEW HAVEN, Conn., March 10, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann
Today's Top Shorts As Tech Stocks Lag With More Rising Bonds
12:08pm, Wednesday, 03'rd Mar 2021
Bond yields are rising again, crushing tech stocks. But the deep learning algorithms at Q.ai have crunched the data to give you a set of Top Shorts for today.
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
09:07am, Monday, 01'st Mar 2021
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -26.92% and -70.27%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Arvinas: Q4 Earnings Insights
07:59am, Monday, 01'st Mar 2021
Shares of Arvinas (NASDAQ:ARVN) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share decreased 76.79% year over year to ($0.99), which missed the estimate of
Arvinas, Inc. (ARVN) Upgraded to Buy: Here's Why
12:53pm, Wednesday, 17'th Feb 2021
Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Arvinas to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day
04:30pm, Monday, 08'th Feb 2021
NEW HAVEN, Conn., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno
Arvinas: Leading In Cutting Edge Protein Degrader Development
03:00pm, Saturday, 02'nd Jan 2021
Arvinas is a leader in protein degrader technology. They have shown first outstanding results in phase 1 trials in breast and prostate cancer.
Arvinas, Inc. Announces Exercise of Underwriters' Option to Purchase Additional Shares
04:30pm, Monday, 28'th Dec 2020
NEW HAVEN, Conn., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its P
Notable Insider Buys In The Week Of Christmas: Foot Locker, GameStop, NetApp And More
01:53pm, Saturday, 26'th Dec 2020
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying c
